Research analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical research company’s stock.
OpGen Price Performance
OPGN stock opened at $2.24 on Tuesday. The company’s 50-day simple moving average is $2.69 and its 200-day simple moving average is $4.11. OpGen has a 52-week low of $1.65 and a 52-week high of $38.40.
OpGen (NASDAQ:OPGN – Get Free Report) last posted its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. OpGen had a negative net margin of 997.34% and a negative return on equity of 1,827.76%. The business had revenue of $0.17 million for the quarter.
Institutional Investors Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Stories
- Five stocks we like better than OpGen
- What Do S&P 500 Stocks Tell Investors About the Market?
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Use the MarketBeat Stock Screener
- 3 Stocks That Could Beat the September Blues
- Stock Market Sectors: What Are They and How Many Are There?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.